Published in Am J Hypertens on January 01, 2005
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int (2009) 1.17
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis (2010) 1.12
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension (2009) 0.99
Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ. Am J Pathol (2011) 0.99
Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther (2009) 0.98
Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options. Pediatr Nephrol (2013) 0.88
The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol (2006) 0.87
Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci (2009) 0.86
Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One (2011) 0.83
An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol (2012) 0.82
The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res (2015) 0.81
Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension (2014) 0.80
Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J (2011) 0.80
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol (2012) 0.80
Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Exp Ther Med (2013) 0.79
Renal microcirculation and calcium channel subtypes. Curr Hypertens Rev (2013) 0.78
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Pediatr Nephrol (2009) 0.77
Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis. PLoS One (2014) 0.77
Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney Int (2015) 0.76
Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner. PLoS One (2015) 0.75
Management of Diabetic Nephropathy in the Elderly: Special Considerations. J Nephrol Ther (2012) 0.75
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. Methodist Debakey Cardiovasc J (2016) 0.75
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (2010) 2.37
Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med (2013) 2.29
Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) (2002) 2.26
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest (2004) 2.24
Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res (2010) 2.18
Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens (2011) 1.75
Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res (2011) 1.72
Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab (2004) 1.69
Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol (2006) 1.62
Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension (2003) 1.59
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens (2014) 1.56
PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism (2002) 1.56
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension (2008) 1.54
Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension (2004) 1.49
Expression of the Na+/H+ exchanger regulatory protein family in genetically hypertensive rats. J Hypertens (2004) 1.49
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res (2010) 1.47
Monosynaptic excitatory connection from the rostral ventrolateral medulla to sympathetic preganglionic neurons revealed by simultaneous recordings. Hypertens Res (2008) 1.47
T-cell-mediated autoimmunity may be involved in fulminant type 1 diabetes. Diabetes Care (2002) 1.45
Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury. Hypertens Res (2007) 1.45
Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem (2010) 1.45
Cloning and characterization of a novel gene promoting ureteric bud branching in the metanephros. Kidney Int (2003) 1.45
High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project. Hum Mol Genet (2007) 1.44
Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study. Am J Hypertens (2011) 1.44
Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun (2008) 1.42
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. Circ J (2009) 1.40
Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. Hypertens Res (2006) 1.39
Ca2+ channel subtypes and pharmacology in the kidney. Circ Res (2007) 1.38
Correlation between serum resistin level and adiposity in obese individuals. Obes Res (2003) 1.36
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res (2004) 1.33
Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res (2007) 1.31
Didecyldimethylammonium chloride induces pulmonary inflammation and fibrosis in mice. Exp Toxicol Pathol (2009) 1.31
C5 palsy following anterior decompression and spinal fusion for cervical degenerative diseases. Eur Spine J (2010) 1.27
Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J (2005) 1.22
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int (2003) 1.21
Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism (2002) 1.18
CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol (2004) 1.16
Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res (2004) 1.13
Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis. J Am Soc Nephrol (2005) 1.11
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res (2008) 1.03
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis (2005) 1.03
Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription. J Biol Chem (2004) 1.03
Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res (2005) 1.02
Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol (2003) 1.02
Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res (2004) 1.02
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther (2008) 1.01
FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr Res (2004) 1.00
Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone. J Vasc Res (2003) 1.00
MPO-ANCA associated crescentic glomerulonephritis with numerous immune complexes: case report. BMC Nephrol (2012) 0.99
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res (2004) 0.98
Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens (2006) 0.98
The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res (2005) 0.98
Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney Int (2003) 0.98
Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res (2012) 0.98
Transient receptor potential channels in rat renal microcirculation: actions of angiotensin II. Kidney Int (2002) 0.97
Electrophysiological properties of rostral ventrolateral medulla neurons in angiotensin II 1a receptor knockout mice. Hypertension (2005) 0.96
Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population. Metabolism (2004) 0.96
Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension (2005) 0.96
Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci (2005) 0.95
GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism (2005) 0.95
Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron (2002) 0.95
Altered renal microvascular response in Zucker obese rats. Metabolism (2002) 0.95
Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol (2007) 0.95
Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem (2006) 0.95
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res (2009) 0.95
Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure. J Am Soc Nephrol (2003) 0.94
Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch. Sci Signal (2011) 0.94
Efficacy and reliability of highly functional open source DICOM software (OsiriX) in spine surgery. J Clin Neurosci (2010) 0.94
Down-regulation of Mcl-1 by inhibition of the PI3-K/Akt pathway is required for cell shrinkage-dependent cell death. Biochem Biophys Res Commun (2002) 0.94
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab (2003) 0.93
Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant (2002) 0.93
Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension. Am J Nephrol (2003) 0.92
High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care (2002) 0.92
Static versus dynamic factors for the development of myelopathy in patients with cervical ossification of the posterior longitudinal ligament. J Clin Neurosci (2010) 0.92
Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. Hypertension (2002) 0.91
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res (2003) 0.91
Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res (2002) 0.91
Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes. J Clin Endocrinol Metab (2003) 0.91
Expression and regulation of nuclear receptor coactivators in glucocorticoid action. Mol Cell Endocrinol (2002) 0.91
Brachial-ankle pulse wave velocity predicts silent cerebrovascular diseases in patients with end-stage renal diseases. J Atheroscler Thromb (2010) 0.90
Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res (2006) 0.90
Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens (2003) 0.90
Functional characterization of podocan, a member of a new class in the small leucine-rich repeat protein family. FEBS Lett (2004) 0.90
NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int (2005) 0.90